Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Reporting Date: June 27, 2025 (Event Date); June 30, 2025 (Closing Date)
Context: The Company announced and closed a public offering of common stock, warrants, and pre-funded warrants to raise capital for clinical trials, patent portfolio maintenance, and working capital.
Key Financial Metrics and Capital Structure
- Net Proceeds: Approximately $4.3 million (after deducting placement agent fees and offering expenses).
- Securities Issued:
- 793,750 shares of Common Stock at $4.00 per share (plus warrants).
- 456,250 Pre-Funded Warrants at $3.999 per warrant (plus warrants).
- Warrant Details:
- Series D Warrants: Exercise price $4.00; 5-year term.
- Series E Warrants: Exercise price $4.00; 18-month term.
- Placement Agent Warrants: 75,000 shares; Exercise price $5.00; 5-year term.
- Potential Additional Proceeds: Approximately $10 million if all warrants are fully exercised on a cash basis.
- Post-Closing Share Count: 1,605,260 shares of Common Stock outstanding.
- Transaction Costs: 7.0% cash fee + 1.0% management fee to Placement Agent (H.C. Wainwright & Co., LLC), plus reimbursement of expenses up to $135,000.
Material Changes Versus Prior Period
This filing represents a discrete capital event rather than a periodic financial report. Consequently, there are no comparative revenue, profit, or cash flow metrics provided in this document. The primary material change is the significant increase in outstanding share count and the addition of warrant obligations following the June 30, 2025 closing.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds will be allocated to funding clinical trials, maintaining/extending the patent portfolio, and general corporate working capital.
- Lock-Up Provisions: The Company is prohibited from issuing Common Stock or convertible securities for 60 days post-closing and from entering into variable rate transactions for one year post-closing.
- Ownership Limitations: Warrant and Pre-Funded Warrant exercise is restricted if the holder would beneficially own more than 4.99% (or 9.99% at election) of outstanding shares.
- Fundamental Transaction Rights: Holders have rights to receive alternative consideration or Black Scholes Value in the event of a fundamental transaction.
Investor Verification Checklist
- Verify the exact dilution impact on existing shareholders given the post-closing share count of 1,605,260.
- Confirm the specific timeline for the clinical trials mentioned as a primary use of proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination rights.
- Monitor the exercise activity of the Series E warrants (18-month term) versus Series D warrants (5-year term).
- Check subsequent filings for any updates on the 60-day lock-up period expiration.